Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite
Plasmodium vivax is the most common species that cause malaria outside of the African continent. The development of an efficacious vaccine would contribute greatly to control malaria. Recently, using bacterial and adenoviral recombinant proteins based on the P. vivax circumsporozoite protein (CSP),...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01275/full |
id |
doaj-697801f110034793978b27aca485aa05 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alba Marina Gimenez Luciana Chagas Lima Luciana Chagas Lima Katia Sanches Françoso Priscila M. A. Denapoli Raquel Panatieri Raquel Panatieri Daniel Y. Bargieri Jean-Michel Thiberge Chiara Andolina Chiara Andolina Francois Nosten Francois Nosten Laurent Renia Ruth S. Nussenzweig Victor Nussenzweig Rogerio Amino Mauricio M. Rodrigues Irene S. Soares |
spellingShingle |
Alba Marina Gimenez Luciana Chagas Lima Luciana Chagas Lima Katia Sanches Françoso Priscila M. A. Denapoli Raquel Panatieri Raquel Panatieri Daniel Y. Bargieri Jean-Michel Thiberge Chiara Andolina Chiara Andolina Francois Nosten Francois Nosten Laurent Renia Ruth S. Nussenzweig Victor Nussenzweig Rogerio Amino Mauricio M. Rodrigues Irene S. Soares Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite Frontiers in Immunology malaria Plasmodium vivax recombinant vaccine circumsporozoite protein prime-boost regimens |
author_facet |
Alba Marina Gimenez Luciana Chagas Lima Luciana Chagas Lima Katia Sanches Françoso Priscila M. A. Denapoli Raquel Panatieri Raquel Panatieri Daniel Y. Bargieri Jean-Michel Thiberge Chiara Andolina Chiara Andolina Francois Nosten Francois Nosten Laurent Renia Ruth S. Nussenzweig Victor Nussenzweig Rogerio Amino Mauricio M. Rodrigues Irene S. Soares |
author_sort |
Alba Marina Gimenez |
title |
Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite |
title_short |
Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite |
title_full |
Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite |
title_fullStr |
Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite |
title_full_unstemmed |
Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite |
title_sort |
vaccine containing the three allelic variants of the plasmodium vivax circumsporozoite antigen induces protection in mice after challenge with a transgenic rodent malaria parasite |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2017-10-01 |
description |
Plasmodium vivax is the most common species that cause malaria outside of the African continent. The development of an efficacious vaccine would contribute greatly to control malaria. Recently, using bacterial and adenoviral recombinant proteins based on the P. vivax circumsporozoite protein (CSP), we demonstrated the possibility of eliciting strong antibody-mediated immune responses to each of the three allelic forms of P. vivax CSP (PvCSP). In the present study, recombinant proteins representing the PvCSP alleles (VK210, VK247, and P. vivax-like), as well as a hybrid polypeptide, named PvCSP-All epitopes, were generated. This hybrid containing the conserved C-terminal of the PvCSP and the three variant repeat domains in tandem were successfully produced in the yeast Pichia pastoris. After purification and biochemical characterization, they were used for the experimental immunization of C57BL/6 mice in a vaccine formulation containing the adjuvant Poly(I:C). Immunization with a recombinant protein expressing all three different allelic forms in fusion elicited high IgG antibody titers reacting with all three different allelic variants of PvCSP. The antibodies targeted both the C-terminal and repeat domains of PvCSP and recognized the native protein on the surface of P. vivax sporozoites. More importantly, mice that received the vaccine formulation were protected after challenge with chimeric Plasmodium berghei sporozoites expressing CSP repeats of P. vivax sporozoites (Pb/PvVK210). Our results suggest that it is possible to elicit protective immunity against one of the most common PvCSP alleles using soluble recombinant proteins expressed by P. pastoris. These recombinant proteins are promising candidates for clinical trials aiming to develop a multiallele vaccine against P. vivax malaria. |
topic |
malaria Plasmodium vivax recombinant vaccine circumsporozoite protein prime-boost regimens |
url |
http://journal.frontiersin.org/article/10.3389/fimmu.2017.01275/full |
work_keys_str_mv |
AT albamarinagimenez vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT lucianachagaslima vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT lucianachagaslima vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT katiasanchesfrancoso vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT priscilamadenapoli vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT raquelpanatieri vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT raquelpanatieri vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT danielybargieri vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT jeanmichelthiberge vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT chiaraandolina vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT chiaraandolina vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT francoisnosten vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT francoisnosten vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT laurentrenia vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT ruthsnussenzweig vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT victornussenzweig vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT rogerioamino vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT mauriciomrodrigues vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite AT irenessoares vaccinecontainingthethreeallelicvariantsoftheplasmodiumvivaxcircumsporozoiteantigeninducesprotectioninmiceafterchallengewithatransgenicrodentmalariaparasite |
_version_ |
1725744012339445760 |
spelling |
doaj-697801f110034793978b27aca485aa052020-11-24T22:29:36ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-10-01810.3389/fimmu.2017.01275283943Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria ParasiteAlba Marina Gimenez0Luciana Chagas Lima1Luciana Chagas Lima2Katia Sanches Françoso3Priscila M. A. Denapoli4Raquel Panatieri5Raquel Panatieri6Daniel Y. Bargieri7Jean-Michel Thiberge8Chiara Andolina9Chiara Andolina10Francois Nosten11Francois Nosten12Laurent Renia13Ruth S. Nussenzweig14Victor Nussenzweig15Rogerio Amino16Mauricio M. Rodrigues17Irene S. Soares18Department of Microbiology, Immunology and Parasitology, Center of Cellular and Molecular Therapy (CTCMol), Federal University of São Paulo, São Paulo, BrazilDepartment of Microbiology, Immunology and Parasitology, Center of Cellular and Molecular Therapy (CTCMol), Federal University of São Paulo, São Paulo, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, BrazilDepartment of Microbiology, Immunology and Parasitology, Center of Cellular and Molecular Therapy (CTCMol), Federal University of São Paulo, São Paulo, BrazilUnit of Malaria Infection and Immunity, Institut Pasteur, Paris, FranceDepartment of Parasitology, University of São Paulo, São Paulo, BrazilDepartment of Parasitology, University of São Paulo, São Paulo, BrazilUnit of Malaria Infection and Immunity, Institut Pasteur, Paris, FranceShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, ThailandCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine Research Building, University of Oxford, Oxford, United KingdomShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, ThailandCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine Research Building, University of Oxford, Oxford, United KingdomSingapore Immunology Network, Biopolis, Agency for Science Technology and Research, Singapore, SingaporeNew York University School of Medicine, New York, NY, United StatesNew York University School of Medicine, New York, NY, United StatesUnit of Malaria Infection and Immunity, Institut Pasteur, Paris, FranceDepartment of Microbiology, Immunology and Parasitology, Center of Cellular and Molecular Therapy (CTCMol), Federal University of São Paulo, São Paulo, BrazilDepartment of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, São Paulo, BrazilPlasmodium vivax is the most common species that cause malaria outside of the African continent. The development of an efficacious vaccine would contribute greatly to control malaria. Recently, using bacterial and adenoviral recombinant proteins based on the P. vivax circumsporozoite protein (CSP), we demonstrated the possibility of eliciting strong antibody-mediated immune responses to each of the three allelic forms of P. vivax CSP (PvCSP). In the present study, recombinant proteins representing the PvCSP alleles (VK210, VK247, and P. vivax-like), as well as a hybrid polypeptide, named PvCSP-All epitopes, were generated. This hybrid containing the conserved C-terminal of the PvCSP and the three variant repeat domains in tandem were successfully produced in the yeast Pichia pastoris. After purification and biochemical characterization, they were used for the experimental immunization of C57BL/6 mice in a vaccine formulation containing the adjuvant Poly(I:C). Immunization with a recombinant protein expressing all three different allelic forms in fusion elicited high IgG antibody titers reacting with all three different allelic variants of PvCSP. The antibodies targeted both the C-terminal and repeat domains of PvCSP and recognized the native protein on the surface of P. vivax sporozoites. More importantly, mice that received the vaccine formulation were protected after challenge with chimeric Plasmodium berghei sporozoites expressing CSP repeats of P. vivax sporozoites (Pb/PvVK210). Our results suggest that it is possible to elicit protective immunity against one of the most common PvCSP alleles using soluble recombinant proteins expressed by P. pastoris. These recombinant proteins are promising candidates for clinical trials aiming to develop a multiallele vaccine against P. vivax malaria.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01275/fullmalariaPlasmodium vivaxrecombinant vaccinecircumsporozoite proteinprime-boost regimens |